This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
IT SOUNDS LIKE the plot of a Hollywood thriller du jour: Terrorists stealthily plant a cache of deadly anthrax spores in the air vents of the New York Stock Exchange. Hundreds die, plunging the global economy into turmoil.
Or consider another scenario: 2 dozen recently hospitalized people, stricken with what at first appears to be a particularly virulent strain of influenza, develop the alarming symptoms of a deadly hemorrhagic fever. By the time the source of the infection is identified as Ebola virus, introduced into blood products by a disgruntled blood bank supervisor whose spouse works at a government research lab, as many as 58 000 people have been significantly exposed to the infection. Some almost certainly carry the contagion with them as they flee the city in panic.
While screenwriters may well be cranking out a Die Hard on Wall Street, these scenarios were created by people who concern
Stephenson J. Confronting a Biological Armageddon: Experts Tackle Prospect of Bioterrorism. JAMA. 1996;276(5):349–351. doi:10.1001/jama.1996.03540050009003
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.